Abstract Thailand is encountering challenges to introduce the high-cost sofosbuvir for chronic hepatitis C treatment as part of the Universal Health Care’s benefit package. This study was conducted in respond to policy demand from the Thai government to assess the value for money and budget impac

Abstract Background Antimicrobial resistance (AMR) is accelerated by the widespread and often indiscriminate use of antimicrobials in humans, animals, and the environment. In 2015, the World Health Organization recognised AMR as one of the top ten global health threats, due to its potential to n

Generic reference cases for economic evaluation (EE) of “cure-based” health technologies may not fit into the new healthcare paradigm of precision medicine (PM). Current EE approaches were challenged by the complex evolving decision space of PM, lack of clinical evidence due to small patient cluster

Introduction Genetic disorders in children contribute to acute hospitalizations and mortality. Early diagnosis is critical for better outcomes but difficult to achieve due to atypical presentations for thousands of potential genetic diseases. Next-generation sequencing (NGS) is a precision

About the study Objective: This study aimed to quantify heterogeneity in the value for money of precision medicine (PM) by application types across contexts and conditions and to quantify sources of heterogeneity to areas of particular promises or concerns as the field of PM moves forward. Methods

Abstract Background and Objectives The Health Intervention and Technology Assessment Program was commissioned to conduct a cost–utility and budget impact analysis of enzyme replacement therapy (ERT) for Gaucher disease types 1 and 3b. The findings from this assessment are to support the decision-m

Objectives: to study the process of implementation of the increasing access to high-cost medicine listed in the Category E2 of the 2008 NLEM policy to practice under public health insurance systems: the Universal Health Coverage scheme (UC), Civil Servant Medical Benefit Scheme (CSMBS), and Social S

Abstract Cardiovascular disease risk assessment Pritaporn Kingkaew*, Tanunya Koopitakkajorn*, Patsri Srisuwan**, Sitaporn Youngkong*, Sripen Tantivess*, and Yot Teerawattananon* *Health Intervention and Technology Assessment Program, Ministry of Public Health, **Outpatient and Family Medicine

Abstract Disease prioritization for inclusion into Thailand’s population-based screening benefit package Sitaporn Youngkong*, Patsri Srisuwan†, Tanunya Koopitakkajorn*, Pritaporn Kingkaew*, Lily Ingsrisawang‡, Det Kedcham§, Sripen Tantivess*, Kanitta Bundhamcharoen#, Yot Teerawattananon* *He

Abstract Population-based screening for nephrosis, nephritis and renal stone in Thailand Patsri Srisuwan*, Tanunya Koopitakkajorn†, Det Kedcham‡, Pritaporn Kingkaew†, Sitaporn Youngkong†, Sripen Tantivess†, and Yot Teerawattananon† *Outpatient and Family Medicine Department, Phramongkutklao Ho